Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation Profiles

被引：39

作者：

Bauerschlag, Dirk O. ^{[1
]}

Ammerpohl, Ole ^{[3
]}

Braeutigam, Karen ^{[1
]}

Schem, Christian ^{[4
]}

Lin, Qiong ^{[2
]}

Weigel, Marion T. ^{[4
]}

Hilpert, Felix ^{[4
]}

Arnold, Norbert ^{[4
]}

Maass, Nicolai ^{[1
]}

Meinhold-Heerlein, Ivo ^{[1
]}

Wagner, Wolfgang ^{[2
]}

机构：

[1] Rhein Westfal TH Aachen, Univ Med Ctr Aachen, Dept Gynecol, DE-52074 Aachen, Germany

[2] Rhein Westfal TH Aachen, Univ Med Ctr Aachen, Dept Cell Biol, Helmholtz Inst Biomed Engn, DE-52074 Aachen, Germany

[3] Univ Med Ctr Schleswig Holstein, Inst Human Genet, Kiel, Germany

[4] Univ Med Ctr Schleswig Holstein, Dept Gynecol, Kiel, Germany

来源：

ONCOLOGY | 2011年 / 80卷 / 1-2期

关键词：

Ovarian cancer; Methylation; Epigenetic modification; Progression-free interval; Microarray; CPG-ISLAND METHYLATION; PHASE-III TRIAL; 1ST-LINE TREATMENT; INTERGROUP TRIAL; GENE-EXPRESSION; PROMOTER HYPERMETHYLATION; PROSTATE-CANCER; CARBOPLATIN; PACLITAXEL; BREAST;

D O I：

10.1159/000327746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: Many patients with ovarian cancer disease relapse within 6 months after adjuvant chemotherapy, with a limited prognosis. Epigenetic modifications have been shown to play an important role in tumor development and formation. Therefore, global analysis of DNA methylation patterns might reveal specific CpG sites that correlate with progression-free interval (PFI) after therapy. Methods: Twenty samples of advanced ovarian cancer with a predominantly serous papillary histological subtype were subjected to DNA methylation profiling. Illumina HumanMethylation27 BeadChip technology was used for simultaneous analysis of 27,578 CpG sites in 1 14,000 genes. Results: Differential DNA methylation of various cytosines correlated with PFI. However, this becomes only significant by classification according to PFI with a cutoff of 1 28 months. Longer survival was associated with hypomethylation at specific CpG sites (e. g. GREB1, TGIF and TOB1) and hypermethylation in other genes (e. g. TMCO5, PTPRN and GUCY2C). Gene ontology analysis revealed that differentially methylated genes were significantly overrepresented in the categories telomere organization, mesoderm development and immune regulation. Conclusion: Epigenetic modifications at specific CpG sites correlate with PFI in ovarian cancer. Therefore, such analysis might be of prognostic value. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：12 / 20

页数：9

共 50 条

[1] Association of somatic DNA methylation variability with progression-free survival and toxicity in ovarian cancer patients
Flanagan, J. M.
Wilhelm-Benartzi, C. S.
Metcalf, M.
Kaye, S. B.
Brown, R.
ANNALS OF ONCOLOGY, 2013, 24 (11) : 2813 - 2818
[2] Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
Lee, C. K.
Simes, R. J.
Brown, C.
Lord, S.
Wagner, U.
Plante, M.
Vergote, I.
Pisano, C.
Parma, G.
Burges, A.
Bourgeois, H.
Hogberg, T.
Bentley, J.
Angleitner-Boubenizek, L.
Ferrero, A.
Richter, B.
Hirte, H.
Gebski, V.
Pfisterer, J.
Pujade-Lauraine, E.
Friedlander, M.
BRITISH JOURNAL OF CANCER, 2011, 105 (08) : 1144 - 1150
[3] Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective
Oza, A. M.
Castonguay, V.
Tsoref, D.
Diaz-Padilla, I.
Karakasis, K.
Mackay, H.
Welch, S.
Weberpals, J.
Hoskins, P.
Plante, M.
Provencher, D.
Tonkin, K.
Covens, A.
Ghatage, P.
Gregoire, J.
Hirte, H.
Miller, D.
Rosen, B.
Maroun, J.
Buyse, M.
Coens, C.
Brady, M. F.
Stuart, G. C. E.
CURRENT ONCOLOGY, 2011, 18 : S20 - S27
[4] Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
Sjoquist, Katrin M.
Lord, Sarah J.
Friedlander, Michael L.
Simes, Robert John
Marschner, Ian C.
Lee, Chee Khoon
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 16
[5] Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer
Gagno, Sara
Bartoletti, Michele
Romualdi, Chiara
Poletto, Elena
Scalone, Simona
Sorio, Roberto
Zanchetta, Martina
De Mattia, Elena
Roncato, Rossana
Cecchin, Erika
Giorda, Giorgio
Toffoli, Giuseppe
PHARMACOGENOMICS, 2020, 21 (14) : 995 - 1010
[6] Proteomic biomarkers for overall and progression-free survival in ovarian cancer patients
Hogdall, Estrid
Fung, Eric T.
Christensen, Ib Jarle
Yip, Christine
Nedergaard, Lotte
Engelholm, Svend Aage
Risum, Signe
Petri, Anette Lykke
Lundvall, Lene
Lomas, Lee
Hogdall, Claus
PROTEOMICS CLINICAL APPLICATIONS, 2010, 4 (12) : 940 - 952
[7] High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer
Veneris, Jennifer Taylor
Darcy, Kathleen M.
Mhawech-Fauceglia, Paulette
Tian, Chunqiao
Lengyel, Ernst
Lastra, Ricardo R.
Pejovic, Tanja
Conzen, Suzanne D.
Fleming, Gini F.
GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 153 - 160
[8] Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials
Matulonis, Ursula A.
Oza, Amit M.
Ho, Tony W.
Ledermann, Jonathan A.
CANCER, 2015, 121 (11) : 1737 - 1746
[9] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
Banerjee, Susana
Kaye, Stan
CURRENT ONCOLOGY REPORTS, 2012, 14 (06) : 483 - 485
[10] Progression-Free Survival Versus Overall Survival in Ovarian Cancer: Where Are We Now?
Susana Banerjee
Stan Kaye
Current Oncology Reports, 2012, 14 : 483 - 485

← 1 2 3 4 5 →